| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 39 | 2018 | 765 | 3.780 |
Why?
|
| Gene Expression Profiling | 37 | 2020 | 322 | 2.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 31 | 2018 | 261 | 2.330 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 23 | 2016 | 160 | 1.300 |
Why?
|
| Appendiceal Neoplasms | 3 | 2020 | 98 | 1.280 |
Why?
|
| Neoplasms | 6 | 2020 | 726 | 1.110 |
Why?
|
| Prognosis | 25 | 2020 | 1497 | 1.090 |
Why?
|
| Immunotherapy | 6 | 2020 | 81 | 0.990 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 259 | 0.850 |
Why?
|
| Humans | 87 | 2020 | 32005 | 0.800 |
Why?
|
| Evolution, Molecular | 2 | 2016 | 34 | 0.800 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 412 | 0.730 |
Why?
|
| Female | 56 | 2020 | 19959 | 0.710 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 91 | 0.660 |
Why?
|
| Iron | 5 | 2017 | 116 | 0.640 |
Why?
|
| Cell Line, Tumor | 29 | 2018 | 726 | 0.640 |
Why?
|
| Receptors, Estrogen | 12 | 2018 | 113 | 0.630 |
Why?
|
| Cell Proliferation | 13 | 2018 | 604 | 0.620 |
Why?
|
| Cluster Analysis | 10 | 2016 | 125 | 0.590 |
Why?
|
| Immunity | 2 | 2016 | 22 | 0.570 |
Why?
|
| Brain Neoplasms | 6 | 2019 | 638 | 0.570 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2019 | 101 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 458 | 0.540 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 24 | 0.520 |
Why?
|
| Computational Biology | 8 | 2020 | 91 | 0.510 |
Why?
|
| Genomics | 5 | 2018 | 85 | 0.490 |
Why?
|
| Mice | 17 | 2020 | 2484 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2017 | 82 | 0.450 |
Why?
|
| Oncogenes | 3 | 2020 | 13 | 0.450 |
Why?
|
| Genes, Immunoglobulin | 1 | 2013 | 4 | 0.440 |
Why?
|
| Major Histocompatibility Complex | 1 | 2013 | 16 | 0.440 |
Why?
|
| Mutation | 5 | 2017 | 489 | 0.440 |
Why?
|
| Animals | 24 | 2020 | 7541 | 0.410 |
Why?
|
| Transcription, Genetic | 8 | 2010 | 137 | 0.400 |
Why?
|
| Algorithms | 8 | 2015 | 495 | 0.400 |
Why?
|
| Transcription Factors | 5 | 2013 | 181 | 0.390 |
Why?
|
| Neoplasm Staging | 7 | 2018 | 447 | 0.380 |
Why?
|
| Middle Aged | 22 | 2020 | 11817 | 0.370 |
Why?
|
| Tamoxifen | 7 | 2015 | 59 | 0.360 |
Why?
|
| Glioblastoma | 3 | 2018 | 156 | 0.360 |
Why?
|
| Genes, ras | 1 | 2009 | 26 | 0.340 |
Why?
|
| YY1 Transcription Factor | 3 | 2016 | 6 | 0.340 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 67 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2019 | 60 | 0.330 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 753 | 0.320 |
Why?
|
| Membrane Proteins | 2 | 2009 | 256 | 0.320 |
Why?
|
| Melanoma | 3 | 2019 | 164 | 0.320 |
Why?
|
| Adenocarcinoma | 5 | 2019 | 308 | 0.310 |
Why?
|
| Adult | 15 | 2020 | 9345 | 0.310 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 495 | 0.300 |
Why?
|
| Liver Neoplasms | 3 | 2019 | 155 | 0.300 |
Why?
|
| Mice, Inbred BALB C | 4 | 2020 | 167 | 0.300 |
Why?
|
| SARS Virus | 2 | 2004 | 7 | 0.300 |
Why?
|
| Survival Rate | 6 | 2020 | 877 | 0.290 |
Why?
|
| Estrogen Receptor alpha | 4 | 2016 | 52 | 0.290 |
Why?
|
| DNA, Bacterial | 1 | 2007 | 27 | 0.290 |
Why?
|
| Treatment Outcome | 12 | 2019 | 3306 | 0.280 |
Why?
|
| Signal Transduction | 8 | 2019 | 682 | 0.280 |
Why?
|
| Antigens, Neoplasm | 3 | 2019 | 45 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 9 | 2016 | 190 | 0.280 |
Why?
|
| Receptor, erbB-2 | 2 | 2018 | 65 | 0.280 |
Why?
|
| Organ Specificity | 2 | 2019 | 81 | 0.270 |
Why?
|
| Bacteria | 1 | 2007 | 48 | 0.270 |
Why?
|
| Cell Line | 4 | 2020 | 435 | 0.270 |
Why?
|
| Systems Biology | 1 | 2006 | 10 | 0.270 |
Why?
|
| Leukocytes | 2 | 2016 | 57 | 0.270 |
Why?
|
| Male | 22 | 2020 | 19165 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2018 | 104 | 0.260 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 876 | 0.260 |
Why?
|
| Models, Biological | 4 | 2019 | 392 | 0.260 |
Why?
|
| Aged | 16 | 2020 | 10301 | 0.260 |
Why?
|
| Genetic Markers | 2 | 2015 | 124 | 0.260 |
Why?
|
| Genome, Human | 6 | 2011 | 132 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2015 | 42 | 0.250 |
Why?
|
| Gene Expression | 7 | 2018 | 338 | 0.250 |
Why?
|
| Models, Genetic | 4 | 2011 | 94 | 0.250 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 41 | 0.240 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2004 | 1 | 0.240 |
Why?
|
| RNA, Small Interfering | 9 | 2019 | 114 | 0.240 |
Why?
|
| Coronavirus | 1 | 2004 | 3 | 0.240 |
Why?
|
| Disease Progression | 6 | 2018 | 594 | 0.230 |
Why?
|
| Cohort Studies | 6 | 2018 | 1817 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 246 | 0.220 |
Why?
|
| Ovarian Neoplasms | 2 | 2017 | 96 | 0.220 |
Why?
|
| Software | 4 | 2008 | 123 | 0.210 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2015 | 71 | 0.210 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 148 | 0.210 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2012 | 25 | 0.210 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1022 | 0.210 |
Why?
|
| Proteins | 2 | 2015 | 144 | 0.200 |
Why?
|
| Disease-Free Survival | 6 | 2014 | 317 | 0.200 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2020 | 18 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 198 | 0.200 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 471 | 0.200 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 538 | 0.200 |
Why?
|
| Sulfides | 3 | 2018 | 26 | 0.190 |
Why?
|
| Caprylates | 3 | 2018 | 27 | 0.190 |
Why?
|
| Lymphatic Metastasis | 3 | 2011 | 166 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2018 | 483 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 147 | 0.180 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 3 | 0.180 |
Why?
|
| Syndecan-1 | 1 | 2019 | 11 | 0.170 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 220 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2020 | 29 | 0.170 |
Why?
|
| Plasma Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 58 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 5 | 2013 | 208 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2020 | 49 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 56 | 0.170 |
Why?
|
| DNA Primers | 4 | 2008 | 91 | 0.170 |
Why?
|
| Microarray Analysis | 3 | 2010 | 19 | 0.170 |
Why?
|
| DNA | 5 | 2011 | 226 | 0.170 |
Why?
|
| Phenotype | 2 | 2016 | 632 | 0.170 |
Why?
|
| Antigens, Nuclear | 1 | 2019 | 7 | 0.170 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2019 | 5 | 0.170 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 17 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2019 | 17 | 0.170 |
Why?
|
| Gene Dosage | 2 | 2009 | 35 | 0.170 |
Why?
|
| Cystatin A | 1 | 2019 | 8 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2011 | 762 | 0.170 |
Why?
|
| RNA Interference | 4 | 2016 | 76 | 0.160 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.160 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 29 | 0.160 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.160 |
Why?
|
| Mice, Nude | 7 | 2013 | 291 | 0.160 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.160 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 20 | 0.160 |
Why?
|
| DNA Repair | 1 | 2019 | 64 | 0.160 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 155 | 0.160 |
Why?
|
| Organoids | 1 | 2019 | 94 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 560 | 0.160 |
Why?
|
| NAD | 1 | 2018 | 27 | 0.160 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 53 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 101 | 0.150 |
Why?
|
| SEER Program | 1 | 2018 | 30 | 0.150 |
Why?
|
| Esophageal Neoplasms | 2 | 2008 | 35 | 0.150 |
Why?
|
| DNA, Viral | 3 | 2008 | 54 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 3 | 2019 | 99 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 23 | 0.140 |
Why?
|
| Calcium | 1 | 2019 | 307 | 0.140 |
Why?
|
| Down-Regulation | 6 | 2019 | 142 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 4 | 2017 | 137 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3509 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
| Recurrence | 3 | 2019 | 263 | 0.140 |
Why?
|
| Estradiol | 4 | 2010 | 136 | 0.140 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2016 | 8 | 0.140 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2016 | 9 | 0.140 |
Why?
|
| DNA Methylation | 6 | 2015 | 141 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 9 | 0.140 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 193 | 0.140 |
Why?
|
| Peptides | 3 | 2016 | 120 | 0.140 |
Why?
|
| Zebrafish | 2 | 2006 | 23 | 0.130 |
Why?
|
| Phosphorylation | 3 | 2016 | 229 | 0.130 |
Why?
|
| Sexual Maturation | 1 | 2016 | 25 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 32 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2016 | 25 | 0.130 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 18 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2019 | 356 | 0.130 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 65 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 70 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 134 | 0.130 |
Why?
|
| Soybean Proteins | 1 | 2016 | 74 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 201 | 0.130 |
Why?
|
| Receptors, Progesterone | 3 | 2018 | 72 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 215 | 0.120 |
Why?
|
| Carboplatin | 1 | 2015 | 48 | 0.120 |
Why?
|
| Epithelial Cells | 5 | 2016 | 141 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2016 | 136 | 0.120 |
Why?
|
| DEAD Box Protein 20 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2015 | 67 | 0.120 |
Why?
|
| Transplantation, Heterologous | 5 | 2013 | 122 | 0.120 |
Why?
|
| Apolipoproteins | 1 | 2016 | 200 | 0.120 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 192 | 0.120 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2004 | 10 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 251 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2012 | 190 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 35 | 0.120 |
Why?
|
| Iron Regulatory Protein 2 | 1 | 2013 | 2 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 263 | 0.120 |
Why?
|
| Cell Movement | 5 | 2014 | 169 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2016 | 249 | 0.110 |
Why?
|
| SOXF Transcription Factors | 1 | 2013 | 4 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 214 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2014 | 81 | 0.110 |
Why?
|
| Estrogen Antagonists | 2 | 2010 | 17 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 104 | 0.110 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2012 | 1 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 57 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 8 | 0.110 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2012 | 1 | 0.100 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2012 | 6 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Cyclins | 1 | 2012 | 6 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 154 | 0.100 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 31 | 0.100 |
Why?
|
| E2F1 Transcription Factor | 1 | 2011 | 3 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 15 | 0.100 |
Why?
|
| Recombinases | 1 | 2011 | 2 | 0.100 |
Why?
|
| 5' Untranslated Regions | 1 | 2011 | 5 | 0.100 |
Why?
|
| G-Quadruplexes | 1 | 2011 | 8 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 9 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2011 | 48 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 9 | 0.100 |
Why?
|
| Transfection | 4 | 2018 | 191 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2008 | 34 | 0.100 |
Why?
|
| Mitochondria | 3 | 2018 | 187 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 582 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 77 | 0.090 |
Why?
|
| Smad Proteins | 1 | 2010 | 7 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2010 | 7 | 0.090 |
Why?
|
| Receptors, Neurotensin | 1 | 2010 | 1 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 96 | 0.090 |
Why?
|
| Neurotensin | 1 | 2010 | 4 | 0.090 |
Why?
|
| beta Catenin | 1 | 2010 | 37 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
| Models, Statistical | 3 | 2006 | 175 | 0.090 |
Why?
|
| Estrogens | 1 | 2011 | 180 | 0.090 |
Why?
|
| Estrogen Receptor beta | 2 | 2007 | 13 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 3990 | 0.090 |
Why?
|
| Camptothecin | 2 | 2017 | 51 | 0.090 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2009 | 4 | 0.090 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 6 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 3 | 2008 | 109 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 35 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 120 | 0.080 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 6 | 0.080 |
Why?
|
| Carcinoma, Large Cell | 1 | 2009 | 4 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 608 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 23 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2019 | 833 | 0.080 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2008 | 5 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Thrombospondins | 1 | 2008 | 6 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2019 | 293 | 0.080 |
Why?
|
| Liver | 2 | 2013 | 484 | 0.080 |
Why?
|
| Carcinoma | 1 | 2008 | 91 | 0.070 |
Why?
|
| Genome, Viral | 2 | 2004 | 10 | 0.070 |
Why?
|
| Protein Binding | 2 | 2019 | 201 | 0.070 |
Why?
|
| Buchnera | 1 | 2007 | 1 | 0.070 |
Why?
|
| Genome, Bacterial | 1 | 2007 | 6 | 0.070 |
Why?
|
| Genes, cdc | 2 | 2008 | 5 | 0.070 |
Why?
|
| Bacteriological Techniques | 1 | 2007 | 16 | 0.070 |
Why?
|
| Arsenic | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cell Cycle | 4 | 2012 | 77 | 0.070 |
Why?
|
| Databases, Genetic | 2 | 2005 | 37 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2007 | 87 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 51 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 36 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 53 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2005 | 6 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2016 | 508 | 0.070 |
Why?
|
| Apoptosis | 3 | 2013 | 360 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 36 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 27 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2005 | 4 | 0.060 |
Why?
|
| Binding Sites | 4 | 2007 | 130 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 115 | 0.060 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2004 | 4 | 0.060 |
Why?
|
| Schizosaccharomyces | 1 | 2004 | 5 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 199 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2006 | 220 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2012 | 189 | 0.060 |
Why?
|
| Response Elements | 1 | 2004 | 16 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2004 | 18 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 55 | 0.060 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2004 | 24 | 0.060 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 2 | 0.060 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2004 | 2 | 0.060 |
Why?
|
| Triiodothyronine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Cerebellum | 1 | 2004 | 26 | 0.060 |
Why?
|
| Vero Cells | 1 | 2004 | 3 | 0.060 |
Why?
|
| Genes | 1 | 2004 | 15 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 48 | 0.060 |
Why?
|
| Base Composition | 1 | 2004 | 10 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 3876 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2004 | 10 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 2636 | 0.060 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 6 | 0.060 |
Why?
|
| Research Design | 2 | 2005 | 313 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 19 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 359 | 0.060 |
Why?
|
| Base Sequence | 3 | 2011 | 252 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2004 | 48 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2004 | 28 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 21 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2004 | 81 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 34 | 0.060 |
Why?
|
| Myocardium | 1 | 2004 | 186 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 73 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2013 | 73 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2004 | 443 | 0.050 |
Why?
|
| Quality Control | 1 | 2002 | 44 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2002 | 71 | 0.050 |
Why?
|
| Cyclin E | 2 | 2012 | 5 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2011 | 40 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2265 | 0.050 |
Why?
|
| DNA Damage | 1 | 2002 | 98 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 767 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 166 | 0.050 |
Why?
|
| Adipose Tissue | 1 | 2004 | 349 | 0.050 |
Why?
|
| Loss of Heterozygosity | 2 | 2012 | 20 | 0.050 |
Why?
|
| Time Factors | 1 | 2006 | 2149 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2011 | 289 | 0.050 |
Why?
|
| Peritoneum | 1 | 2020 | 33 | 0.050 |
Why?
|
| Immune System Phenomena | 1 | 2020 | 5 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 918 | 0.040 |
Why?
|
| Cell Survival | 2 | 2010 | 284 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 48 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 40 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2012 | 170 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 107 | 0.040 |
Why?
|
| Acrylamides | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hydroxamic Acids | 2 | 2009 | 21 | 0.040 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 13 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2018 | 26 | 0.040 |
Why?
|
| Tretinoin | 1 | 2018 | 34 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 22 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2018 | 19 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 19 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 41 | 0.040 |
Why?
|
| Cytarabine | 1 | 2018 | 55 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 545 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 30 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2018 | 98 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 16 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 70 | 0.040 |
Why?
|
| Piperidines | 1 | 2018 | 118 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 24 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 29 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 19 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 30 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 62 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 2282 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 46 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 154 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 44 | 0.040 |
Why?
|
| Lipids | 1 | 2018 | 232 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 58 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 81 | 0.040 |
Why?
|
| Cytokines | 1 | 2018 | 256 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 74 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 259 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2017 | 84 | 0.030 |
Why?
|
| Phytoestrogens | 1 | 2016 | 23 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 80 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 11 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 80 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 74 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2015 | 14 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 161 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 81 | 0.030 |
Why?
|
| Species Specificity | 2 | 2005 | 90 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2016 | 363 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2015 | 82 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2015 | 134 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 8 | 0.030 |
Why?
|
| Prostate | 1 | 2015 | 68 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 30 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2016 | 434 | 0.030 |
Why?
|
| Leukemia | 1 | 2014 | 40 | 0.030 |
Why?
|
| Apoferritins | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, Transferrin | 1 | 2013 | 10 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 355 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 301 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 276 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 29 | 0.030 |
Why?
|
| G2 Phase | 2 | 2004 | 17 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 469 | 0.030 |
Why?
|
| Diet | 1 | 2016 | 391 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2013 | 103 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 163 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 407 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Cyclin D2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 71 | 0.030 |
Why?
|
| Internet | 2 | 2004 | 195 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 22 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1166 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cell Shape | 1 | 2012 | 28 | 0.030 |
Why?
|
| Cations, Monovalent | 1 | 2011 | 1 | 0.030 |
Why?
|
| DNA Footprinting | 1 | 2011 | 1 | 0.030 |
Why?
|
| GC Rich Sequence | 1 | 2011 | 1 | 0.030 |
Why?
|
| Circular Dichroism | 1 | 2011 | 30 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 85 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2011 | 17 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 78 | 0.020 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2011 | 1 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 13 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2011 | 15 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 981 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 82 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 92 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2010 | 20 | 0.020 |
Why?
|
| Retinal Dehydrogenase | 1 | 2010 | 2 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2010 | 15 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2010 | 14 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 52 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2010 | 29 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 447 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 108 | 0.020 |
Why?
|
| Cisplatin | 1 | 2010 | 76 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 34 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 247 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2009 | 3 | 0.020 |
Why?
|
| African Americans | 1 | 2017 | 1425 | 0.020 |
Why?
|
| Breast | 1 | 2010 | 68 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2009 | 2 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 663 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2008 | 28 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 684 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 210 | 0.020 |
Why?
|
| Artifacts | 1 | 2008 | 39 | 0.020 |
Why?
|
| Chromosome Segregation | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 18 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 12 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 40 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2008 | 21 | 0.020 |
Why?
|
| Epithelium | 1 | 2008 | 30 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1328 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 68 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 248 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 1062 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 51 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2006 | 19 | 0.020 |
Why?
|
| Premenopause | 1 | 2006 | 44 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2006 | 55 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 11 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2005 | 20 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 3539 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 70 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 35 | 0.020 |
Why?
|
| RNA Probes | 1 | 2005 | 4 | 0.020 |
Why?
|
| DNA Probes | 1 | 2005 | 19 | 0.020 |
Why?
|
| Mucins | 1 | 2005 | 18 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 285 | 0.020 |
Why?
|
| Genome, Fungal | 1 | 2004 | 1 | 0.020 |
Why?
|
| ras-GRF1 | 1 | 2004 | 1 | 0.020 |
Why?
|
| G1 Phase | 1 | 2004 | 11 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2004 | 7 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2004 | 30 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2004 | 12 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 24 | 0.020 |
Why?
|
| S Phase | 1 | 2004 | 15 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2005 | 59 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2004 | 20 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2005 | 30 | 0.020 |
Why?
|
| Temperature | 1 | 2004 | 55 | 0.020 |
Why?
|
| Software Design | 1 | 2004 | 6 | 0.020 |
Why?
|
| Genome | 1 | 2004 | 38 | 0.020 |
Why?
|
| Chromatin | 1 | 2004 | 25 | 0.020 |
Why?
|
| Singapore | 1 | 2004 | 10 | 0.010 |
Why?
|
| Cell Separation | 1 | 2004 | 92 | 0.010 |
Why?
|
| Laboratories | 1 | 2004 | 15 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 185 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 55 | 0.010 |
Why?
|
| Phylogeny | 1 | 2004 | 56 | 0.010 |
Why?
|
| Postmenopause | 1 | 2006 | 430 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2004 | 108 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 367 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 733 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2004 | 156 | 0.010 |
Why?
|
| Aphidicolin | 1 | 2002 | 1 | 0.010 |
Why?
|
| Mitosis | 1 | 2002 | 25 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 93 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 71 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 633 | 0.010 |
Why?
|